244 related articles for article (PubMed ID: 24262022)
41. Quantifying spontaneous metastasis in a syngeneic mouse melanoma model using real time PCR.
Deng W; McLaughlin SL; Klinke DJ
Analyst; 2017 Aug; 142(16):2945-2953. PubMed ID: 28725894
[TBL] [Abstract][Full Text] [Related]
42. ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma.
Miao X; Zhao Y
Oncol Rep; 2016 Apr; 35(4):2131-40. PubMed ID: 26820593
[TBL] [Abstract][Full Text] [Related]
43. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
[TBL] [Abstract][Full Text] [Related]
44. Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.
Ashtekar A; Huk D; Magner A; La Perle KMD; Boucai L; Kirschner LS
J Clin Endocrinol Metab; 2018 Nov; 103(11):4135-4145. PubMed ID: 30165401
[TBL] [Abstract][Full Text] [Related]
45. Be Aware of the Patient With Benign Follicular Thyroid Lesion Histology and Rising Thyroglobulin Level.
Slutzky-Shraga I; Sternov Y; Robenshtock E; Tzvetov G; Benbassat C; Hirsch D
Endocr Pract; 2018 Aug; 24(8):740-745. PubMed ID: 30106632
[TBL] [Abstract][Full Text] [Related]
46. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
47. Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review).
Hoelting T; Goretzki PE; Duh QY
Oncol Rep; 2001; 8(1):3-8. PubMed ID: 11115561
[TBL] [Abstract][Full Text] [Related]
48. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
49. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
51. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
[TBL] [Abstract][Full Text] [Related]
52. RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.
Rahbari R; Kitano M; Zhang L; Bommareddi S; Kebebew E
J Clin Endocrinol Metab; 2013 Mar; 98(3):E446-54. PubMed ID: 23393170
[TBL] [Abstract][Full Text] [Related]
53. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.
Sponziello M; Lavarone E; Pegolo E; Di Loreto C; Puppin C; Russo MA; Bruno R; Filetti S; Durante C; Russo D; Di Cristofano A; Damante G
Endocrinology; 2013 Sep; 154(9):3043-53. PubMed ID: 23751876
[TBL] [Abstract][Full Text] [Related]
54. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
[TBL] [Abstract][Full Text] [Related]
55. [The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm].
Zhang J; Li Y; Lyu N; Ying JM
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):594-598. PubMed ID: 31434450
[No Abstract] [Full Text] [Related]
56. Influence of mesenchymal stem cells on metastasis development in mice in vivo.
Meleshina AV; Cherkasova EI; Shirmanova MV; Klementieva NV; Kiseleva EV; Snopova LВ; Prodanets NN; Zagaynova EV
Stem Cell Res Ther; 2015 Feb; 6(1):15. PubMed ID: 25888992
[TBL] [Abstract][Full Text] [Related]
57. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
58. Renal metastasis from papillary thyroid microcarcinoma.
Liou MJ; Lin JD; Chung MH; Liau CT; Hsueh C
Acta Otolaryngol; 2005 Apr; 125(4):438-42. PubMed ID: 15823819
[TBL] [Abstract][Full Text] [Related]
59. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
60. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
